StereotaxisSTXS
Recorded

Stereotaxis 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration42 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon. Thank you for joining us for Stereotaxis' third quarter 2026 earnings conference call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update these statements. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments following the presentation.

Operator

As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.

David FischelChairman and CEO

Thank you, operator, and good afternoon, everyone. On our last few calls, I provided significant background on our innovation and commercial strategy. I want to keep today's prepared remarks more focused on our near-term priorities, key updates from the past quarter, and expected upcoming milestones. It's a busy and exciting period. Our near-term priority is to drive forward two major business model transformations. The first is shifting from capital systems that require long sales and construction timelines, having a portfolio of systems that can be easily installed and are therefore significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide us with a robust recurring revenue opportunity.

David FischelChairman and CEO

We are fully focused on pushing these two major structural transformations forward such that they are established realities and a solid foundation upon which to build a healthy, high-growth, profitable company. On the capital side, the two primary innovations that are beginning to have a commercial impact and advance this structural transformation are GenesisX and Synchrony. GenesisX is our newest robotic system for minimally invasive endovascular procedures. It can be installed in existing operating rooms without the need for construction or the purchase of a specific integrated X-ray. Synchrony is our consolidated digital cockpit for the operating room, enhancing procedural workflow and introducing intraoperative connectivity and augmented intelligence. Our revenue growth in the third quarter benefited from the initial commercial impact of these two technologies. System revenue of $3 million in the quarter was up 60% compared to the third quarter of last year.

David FischelChairman and CEO

We benefited from partial revenue recognition from the first GenesisX system sale in the U.S., the first Genesis system sold in China, and multiple Synchrony systems sold and installed in the U.S. Installing the first GenesisX systems and demonstrating their performance and reliability in the real-world setting will be significant milestones. We are prepared to install the first GenesisX system in the U.S. this month and expect to install the first GenesisX system in Europe soon afterwards. A clear requirement for the broad adoption of GenesisX by hospital customers is ensuring it can be used interoperably with various standard X-rays. We had two significant recent milestones supporting this broad interoperability. in August, we received FDA clearance for an upgraded version of GenesisX, approved to work in a compatible fashion with any non-modified, non-integrated X-ray.

David FischelChairman and CEO

Our systems have never had this capability or broad regulatory label, with all our previous robots being tied to a specific X-ray modified to work with us. At the end of October, we were delighted to enter into collaboration with Canon, a global leader in X-ray technology. Our collaboration supports compatibility of GenesisX with their X-ray, along with co-marketing of our systems together and opportunities for other technology and commercial collaborations. The first U.S. GenesisX system will be installed alongside Canon's X-ray, and we are looking forward to this first commercial installation together. Beyond the already announced first U.S. and European GenesisX systems, we have visibility to an additional GenesisX installation early in 2027 that will work in a compatible fashion with an X-ray system from another major manufacturer.

David FischelChairman and CEO

We have a pipeline of a couple dozen GenesisX opportunities and expect commercial activity to increase meaningfully as the first systems demonstrate their performance in real-world use. The second key capital system in our portfolio is the Synchrony digital operating room system. This past quarter was the first full quarter of commercialization following FDA approval in spring. We had multiple Synchrony systems ordered, sold, and installed in the quarter, alongside robots, but predominantly as standalone systems installed in non-robotic cath labs. We were particularly excited by the first multi-lab installation of Synchrony with Abbott Northwestern Hospital in Minneapolis, becoming the first hospital in the world to adopt the Synchrony system as a standardized technology across its four cardiology catheterization labs. We have a robust pipeline of Synchrony systems, with a few dozen identified as actionable within the next year.

David FischelChairman and CEO

GenesisX and Synchrony are independent, though synergistic opportunities to grow capital revenue significantly. We are just in the earliest stages of commercializing these systems, but are excited by the recent accomplishments and near-term milestones, and expect more consistent and substantial capital activity in the coming months. The development and commercialization of a portfolio of robotically steered interventional catheters is the other major transformation we are driving forward. We will have several million dollars in robotic catheter revenue this year, up from just a few hundred thousand dollars last year. This is despite significant supply constraints and the challenge of our customers needing to transition relatively abruptly from the historic J&J ecosystem they've been dependent on. Robotic catheter revenue in the third quarter was up over 20% sequentially from the second quarter and up over 400% from a year ago, but underperformed our expectation.

David FischelChairman and CEO

Osypka, our contract manufacturer in Germany, has not been able to meet its forecast for production of MAGiC catheters. We saw no increase in MAGiC shipments in the third quarter versus the second quarter. In Europe, we are fortunate to have two other robotic magnetic catheters that we can offer to customers through exclusive distribution rights we established with industry partners. We have pivoted to fully focusing on these catheters in Europe, and by doing so, will better serve our European customers and will preserve limited MAGiC production from Osypka for the U.S. In the U.S., MAGiC remains the only available catheter for customers, and we have worked hard alongside our customers to manage the painful reality of limited supply. We entered the fourth quarter with a backlog of approximately $1.9 million in disposable orders we could not convert to revenue due to supply constraints.

David FischelChairman and CEO

While continuing to work with Osypka to improve their processes, we are also fully aware of the need to establish additional supply capacity. We reached significant regulatory milestones in that effort in recent months and see the opportunity for the shortage to be resolved in the earlier parts of 2027. Even with no improvement in shipments from Osypka, we are confident in achieving a high watermark of recurring revenue this quarter, primarily driven by the shift to our alternative catheters in Europe. It is important to keep in mind the context for our annual growth in disposable revenue. It reflects significant contribution from an improved razor blade business model, counteracting significant procedural pressure from limited catheter supply, and the challenging transition away from J&J. As we continue to address these headwinds and constraints, we expect the power of the attractive recurring revenue business model to become much more visible and impactful.

David FischelChairman and CEO

While these two structural transformations in capital systems and disposable revenue are our clear near-term focus, we continue to advance a broad innovation pipeline that will enhance our clinical impact and commercial opportunity. This progress is often underappreciated, but is a source of significant excitement internally and among our physician customers and industry partners. Several of the most impactful innovation efforts internally include a future generation of GenesisX that will be fully wireless, battery-operated, and mobile, a more robust portfolio of electrophysiology catheters, including robotic pulsed field ablation, a pipeline of robotically steered wires and catheters for the cardiology and neurointerventional fields, and AI efforts that will incorporate intelligent decision support features into Synchrony and automation to our robotic platforms. In addition to these internal efforts, the most notable contribution to our innovation pipeline came with the closing of the Robocath acquisition last quarter.

David FischelChairman and CEO

We have been busy working alongside our new Robocath teammates to develop their next-generation robot. The R-Star system is a mechanical robot with essentially human-like fingers that can hold and manipulate five catheters and interventional devices in tandem. It is being designed to work as an independent robotic system for the interventional cardiology and neurointerventional fields, but will also work synergistically with Stereotaxis's robotic technologies. Clinical data from a first-in-human study performed with the R-Star system was presented a week ago at the TCT conference. It showed superb clinical results and safety across a full range of complex coronary angioplasty procedures.

David FischelChairman and CEO

Our near-term work with Robocath is focused on four specific efforts: addressing remaining engineering work needed to reach formal design freeze, establishing a reliable supply chain, defining more clearly a continuous innovation pipeline for R-One following initial launch, and enhancing R-One with Stereotaxis's existing advanced software architecture, Synchrony digital cockpit, and SynX telesurgery system. All these innovations I just shared are relatively advanced. Some will have an initial commercial impact in 2027, and all of them are in a mature enough stage where they should have a commercial impact within the next two years. Our ability to advance so many complex technologies in parallel is a testament to the strength of our team. It highlights our global leadership in the technological race to make endovascular robotics an impactful reality in the large unaddressed markets of electrophysiology, interventional cardiology, and neurointerventions.

David FischelChairman and CEO

Before handing the call to Kim to discuss our financial results, I want to step back for a moment and make one general comment. I know that it may not feel like it from the vantage view of the capital markets, but this is a highly exciting period for Stereotaxis. In my nearly 10 years here, I have never felt as proud of what we have accomplished and as confident about the opportunity ahead of us. There are obviously stresses and challenges that weigh on us, but these are being addressed in a diligent fashion. It has been a long journey with some bumps on the path, but what we have brought together is remarkable. The core technology ecosystem we developed and our in-house capabilities to expand on those technologies are a very solid foundation. Our vision for what Stereotaxis can accomplish is becoming increasingly clear and tangible.

David FischelChairman and CEO

We are enthusiastically advancing forward. Kim will now provide commentary on our financial results, and then I'll make a few financial comments as well before opening the call to Q&A.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day